The phase 3 COMBI-v trial further confirmed that the combination of BRAF and MEK inhibitors significantly improved progression-free survival and response rates compared to BRAF monotherapy in ALM patients with BRAF mutations [51]. The gene discussed is MAP2K7; the disease is acral lentiginous melanoma.